74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Fagron
Open
SectorHealthcare
19.36 0.94
Overview
Share price change
24h
Min
19.08
Max
19.34
Income | -298K 40M |
|---|---|
Sales | 13M 443M |
P/E Sector Avg | 17.164 57.333 |
Dividend yield | 1.55 |
Profit margin | 9.066 |
Employees | 3,828 |
EBITDA | -4.3M 71M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +20.59% upside |
Dividend yield Sector Avg | 1.55% 2.63% |
|---|
Market Cap | -16M 1.4B |
|---|---|
Previous open | 18.42 |
Previous close | 19.36 |
Fagron Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Fagron Forecast
Price Target
By TipRanks
20.59% upside
12 Months Forecast
Average 19.5 EUR 20.59%
High 19.5 EUR
Low 19.5 EUR
Based on 1 Wall Street analysts offering 12 month price targets forFagron - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Fagron
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
